Published in Can J Infect Dis on May 01, 2000
Assuring vaccine safety: A celebration of 10 years of progress with the IMPACT project. Paediatr Child Health (2002) 0.75
Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. Lancet (1997) 4.32
Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T. Lancet (1994) 2.78
Systemic Haemophilus influenzae disease: an overview. J Pediatr (1979) 1.68
Effect of nationwide vaccination of 3-month-old infants in The Netherlands with conjugate Haemophilus influenzae type b vaccine: high efficacy and lack of herd immunity. J Pediatr (1997) 1.64
Haemophilus influenzae invasive disease in the United States, 1994-1995: near disappearance of a vaccine-preventable childhood disease. Emerg Infect Dis (1998) 1.57
IMPACT monitoring network: A better mousetrap. Can J Infect Dis (1993) 1.52
Severe Haemophilus influenzae infections. Am J Dis Child (1975) 1.42
Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections. Pediatr Infect Dis J (1996) 1.38
Haemophilus influenzae type b meningitis: manifestations and long term sequelae. Pediatr Infect Dis J (1987) 1.26
Safety and immunogenicity of Haemophilus influenzae vaccine (tetanus toxoid conjugate) administered concurrently or combined with diphtheria and tetanus toxoids, pertussis vaccine and inactivated poliomyelitis vaccine to healthy infants at two, four and six months of age. Pediatr Infect Dis J (1994) 1.07
Haemophilus influenzae meningitis in Manitoba and the Keewatin District, NWT: potential for mass vaccination. CMAJ (1988) 0.96
High antibody responses to booster doses of either Haemophilus influenzae capsular polysaccharide or conjugate vaccine after primary immunization with conjugate vaccines. J Infect Dis (1992) 0.95
Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: plain Haemophilus influenzae type b-PRP (Hib) boosters children primed with a tetanus-conjugate Hib-DTPa-HBV combined vaccine. Eur J Pediatr (1997) 0.91
National Advisory Committee on Immunization (NACI). Statement on Haemophilus influenzae type B conjugate vaccines for use in infants and children. Can Commun Dis Rep (1992) 0.90
Haemophilus influenzae type B disease at 11 pediatric centres, 1996-1997. Can Commun Dis Rep (1998) 0.90
Invasive Haemophilus influenzae type B infections: a continuing challenge. Am J Infect Control (1990) 0.84
Can Haemophilus influenzae type b-tetanus toxoid conjugate vaccine be combined with diphtheria toxoid-pertussis vaccine-tetanus toxoid? CMAJ (1993) 0.83
Evaluation of booster doses of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in 18-month-old children. Vaccine (1995) 0.83
Study of booster doses of two Haemophilus influenzae type b conjugate vaccines including their interchangeability. Vaccine (1996) 0.83
Haemophilus influenzae type b infection in childhood: history of bacteremia and antigenemia. Infect Immun (1985) 0.82
Protective efficacy of Haemophilus influenzae type b polysaccharide and conjugate vaccines in children 18 months of age and older. JAMA (1991) 0.81
Haemophilus b conjugate vaccine. CMAJ (1988) 0.78
Nurse case management to improve glycemic control in diabetic patients in a health maintenance organization. A randomized, controlled trial. Ann Intern Med (1998) 7.26
A nurse is suspended. BMJ (1996) 5.93
Vaccine-induced escape mutant of hepatitis B virus. Lancet (1990) 5.31
Outbreak of toxoplasmosis associated with municipal drinking water. The BC Toxoplasma Investigation Team. Lancet (1997) 4.36
Stringent spacing requirements for transcription activation by CRP. Cell (1990) 3.52
SIDS and the toxic gas theory revisited. N Z Med J (1998) 2.68
Vaccine storage and handling. Knowledge and practice in primary care physicians' offices. Can Fam Physician (1995) 2.34
Antibiotic uptake into gram-negative bacteria. Eur J Clin Microbiol Infect Dis (1988) 2.30
Assessment of a universal, school-based hepatitis B vaccination program. JAMA (1995) 2.23
Effects of brief counselling among male heavy drinkers identified on general hospital wards. Drug Alcohol Rev (1996) 2.23
Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol (2001) 2.20
Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem (2000) 2.02
Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother (1998) 2.00
Multinational outbreak of Salmonella enterica serotype Newport infections due to contaminated alfalfa sprouts. JAMA (1999) 1.92
1,3-Dialkyl-8-(p-sulfophenyl)xanthines: potent water-soluble antagonists for A1- and A2-adenosine receptors. J Med Chem (1985) 1.87
Musculoskeletal ultrasound training in rheumatology: the Belfast experience. Rheumatology (Oxford) (2005) 1.86
Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract (2012) 1.84
The role of two surface exposed loops in transcription activation by the Escherichia coli CRP and FNR proteins. Nucleic Acids Res (1991) 1.83
Partner notification for sexually transmitted diseases: an overview of the evidence. Can J Public Health (1995) 1.80
Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol (1998) 1.72
Evaluation of an institution-based protocol for postpartum rubella vaccination. CMAJ (2001) 1.71
The functional subunit of a dimeric transcription activator protein depends on promoter architecture. EMBO J (1994) 1.70
Predictive validity of the Readiness to Change Questionnaire. Addiction (1993) 1.65
Epstein-Barr virus leader protein enhances EBNA-2-mediated transactivation of latent membrane protein 1 expression: a role for the W1W2 repeat domain. J Virol (1997) 1.64
Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology (2001) 1.61
Interactions between the Escherichia coli cyclic AMP receptor protein and RNA polymerase at class II promoters. Mol Microbiol (1993) 1.60
Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob Agents Chemother (1999) 1.60
The structure and physiology of gastrointestinal mucus. Adv Exp Med Biol (1982) 1.59
Simultaneous presentation of Kawasaki disease and toxic shock syndrome in an adolescent male. Pediatr Infect Dis J (1996) 1.48
Cost of chickenpox in Canada: part I. Cost of uncomplicated cases. Pediatrics (1999) 1.47
Expanding the epidemiologic profile: risk factors for active tuberculosis in people immigrating to Ontario. CMAJ (2000) 1.44
The fractional shortening-velocity ratio: validation of a new echocardiographic Doppler method for identifying patients with significant aortic stenosis. J Am Coll Cardiol (1990) 1.43
Invited article: CO2 laser production of fused silica fibers for use in interferometric gravitational wave detector mirror suspensions. Rev Sci Instrum (2011) 1.42
Pentoxifylline for treating venous leg ulcers. Cochrane Database Syst Rev (2002) 1.41
Role of Pseudomonas aeruginosa outer membrane protein OprH in polymyxin and gentamicin resistance: isolation of an OprH-deficient mutant by gene replacement techniques. Antimicrob Agents Chemother (1992) 1.41
Successful closure of coronary artery perforation using makeshift stent sandwich. Catheter Cardiovasc Interv (2001) 1.39
Antibiotic dosages in the treatment of group A streptococcal infections. Clin Pediatr (Phila) (1992) 1.37
Outcome of pulmonary tuberculosis treatment in the tertiary care setting--Toronto 1992/93. Tuberculosis Treatment Completion Study Group. CMAJ (1999) 1.37
Cytotoxic T-cell responses to the nucleocapsid proteins of HBV in chronic hepatitis. Evidence that antibody modulation may cause protracted infection. J Hepatol (1987) 1.33
Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia. Blood (1997) 1.31
HLA class I antigens on the hepatocyte membrane during recovery from acute hepatitis B virus infection and during interferon therapy in chronic hepatitis B virus infection. Hepatology (1986) 1.31
Prevention of influenza and pneumococcal pneumonia in Canadian long-term care facilities: how are we doing? CMAJ (2001) 1.31
Comparison of promoter activities in Escherichia coli and Pseudomonas aeruginosa: use of a new broad-host-range promoter-probe plasmid. FEMS Microbiol Lett (1990) 1.31
A high-resolution multimode digital microscope system. Methods Cell Biol (1998) 1.30
Meningococcal disease in Ontario during the winter of 1988-1989. Can Dis Wkly Rep (1989) 1.29
Lower respiratory tract infections in Inuit infants on Baffin Island. CMAJ (2001) 1.28
Low-level exposures to lead: the Sydney lead study. Dev Med Child Neurol (1989) 1.28
The Immunization Monitoring Program Active (IMPACT) prospective five year study of Canadian children hospitalized for chickenpox or an associated complication. Pediatr Infect Dis J (2000) 1.27
Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology (1996) 1.27
Epidemiological features of pertussis in hospitalized patients in Canada, 1991-1997: report of the Immunization Monitoring Program--Active (IMPACT). Clin Infect Dis (1999) 1.26
The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis. J Clin Invest (1993) 1.25
Abortion and perinatal sepsis associated with campylobacter infection. Rev Infect Dis (1986) 1.22
Intention of parents to have male children vaccinated with the human papillomavirus vaccine. Sex Transm Infect (2008) 1.21
Tuberculosis screening in migrants in selected European countries shows wide disparities. Eur Respir J (2006) 1.20
The effects of mosquito transmission and population bottlenecking on virulence, multiplication rate and rosetting in rodent malaria. Int J Parasitol (2005) 1.20
Genetic analysis of multiplex rheumatoid arthritis families. Genes Immun (1999) 1.18
Historic low Haemophilus influenzae type B case tally--Canada 2000. Can Commun Dis Rep (2001) 1.17
Atypical and complicated Kawasaki disease in infants. Do we need criteria? West J Med (1995) 1.17
Sequelae of acute bacterial meningitis in children treated for seven days. Pediatrics (1986) 1.17
Surface characteristics of Pseudomonas aeruginosa grown in a chamber implant model in mice and rats. Infect Immun (1989) 1.15
Pentamidine inhibits mitochondrial intron splicing and translation in Saccharomyces cerevisiae. RNA (2000) 1.15
A unique insertion in the S gene of surface antigen--negative hepatitis B virus Chinese carriers. Hepatology (1995) 1.14
Diversifying microbial natural products for drug discovery. Appl Microbiol Biotechnol (2003) 1.13
Adults with Prader-Willi syndrome: abnormalities of sleep and behaviour. J R Soc Med (1989) 1.13
Evaluation of facial expression in acute pain in cats. J Small Anim Pract (2014) 1.12
Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer (2011) 1.12
The cost effectiveness of combined rapid tests (Multistix) in screening for urinary tract infections. J R Soc Med (1994) 1.12
An automated segmentation approach for highlighting the histological complexity of human lung cancer. Ann Biomed Eng (2010) 1.11
Assessment of in-flight transmission of SARS--results of contact tracing, Canada. Can Commun Dis Rep (2003) 1.11
Nonlinear anisotropic diffusion filtering of three-dimensional image data from two-photon microscopy. J Biomed Opt (2004) 1.11
A family with attenuated familial adenomatous polyposis due to a mutation in the alternatively spliced region of APC exon 9. Hum Mutat (1998) 1.11
Hsp-70 is closely associated with the transferrin receptor in exosomes from maturing reticulocytes. Biochem J (1995) 1.10
Hand arthritis in systemic lupus erythematosus: an ultrasound pictorial essay. Lupus (2006) 1.09
Controlled trial of new formulae for feeding low birth weight infants. Early Hum Dev (1986) 1.09
Invasive pneumococcal infections among Canadian aboriginal children. Can Commun Dis Rep (2003) 1.05
An outbreak of human blastomycosis: the epidemiology of blastomycosis in the Kenora catchment region of Ontario, Canada. Can Commun Dis Rep (2000) 1.05
Detailed mapping of a congenital heart disease gene in chromosome 3p25. J Med Genet (2000) 1.05
Arthritis associated with Haemophilus influenzae meningitis: septic or reactive? J Pediatr (1986) 1.04
The Epstein-Barr virus promoter initiating B-cell transformation is activated by RFX proteins and the B-cell-specific activator protein BSAP/Pax5. J Virol (2000) 1.04
A trial of the effect of nimodipine on outcome after head injury. Acta Neurochir (Wien) (1991) 1.04
Analysis of meningococcal serogroup C-specific antibody levels in British Columbian children and adolescents. J Infect Dis (1996) 1.03
Neurobehavioural consequences of prenatal low level exposures to lead. Neurotoxicol Teratol (1989) 1.03
Omental actinomycosis presenting with right lower quadrant abdominal pain. J Clin Pathol (2004) 1.02
The role of aminopeptidases in haemoglobin degradation in Plasmodium falciparum-infected erythrocytes. Mol Biochem Parasitol (2001) 1.02
Erythrocyte morphology in patients with sickle cell anemia and pulmonary emboli. JAMA (1968) 1.02
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report. Ann Oncol (2012) 1.01
The effect of F-actin on the binding and hydrolysis of guanine nucleotide by Dictyostelium elongation factor 1A. J Biol Chem (1998) 1.01
Validation and reproducibility of a high-resolution three-dimensional facial imaging system. Br J Oral Maxillofac Surg (2007) 1.01
Hybrid drugs for malaria. Curr Pharm Des (2009) 1.00
New gene for autosomal recessive non-syndromic hearing loss maps to either chromosome 3q or 19p. Am J Med Genet (1997) 1.00
Neutralization of hepatitis B virus infectivity by a murine monoclonal antibody: an experimental study in the chimpanzee. J Med Virol (1985) 1.00
Effects of the antimitotic natural product dolastatin 10, and related peptides, on the human malarial parasite Plasmodium falciparum. J Antimicrob Chemother (2003) 0.98
Disseminated bacille Calmette-Guérin infection: three recent Canadian cases. IMPACT. Immunization Monitoring Program, Active. Can Commun Dis Rep (1998) 0.97
Influenza in Canada: 2007-2008 season update. Can Commun Dis Rep (2008) 0.97